珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
2023年09月20日 22:21:14来源:作者:

Not intended for US-, Canada- or UK-based media

Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success
Access to end-to-end AI platform capabilities to generate novel development candidates in oncology, neurology and immunology
AI-powered R&D integral part of delivering on ambition of bringing more medicines to more patients, faster

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts. The partnerships, with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., are expected to generate several novel clinical development drug candidates with first-in-class and best-in-class potential in key therapeutic areas of oncology, neurology and immunology.

“With the convergence of science, data, and AI, we're determined to fast-track the development of new and truly innovative candidates, forging a path to previously unimaginable medical breakthroughs,” said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business sector of Merck. “The partnerships with industry-leading AI technology firms BenevolentAI and Exscientia will complement our internal research capabilities and expertise, aligning with our broader strategy to enhance R&D productivity and the output of our pipeline in a sustainable manner.”

Under the terms of the agreements, three potential first-in-class and best-in-class targets have been selected to initiate each partnership with the possibility of identifying and nominating additional targets in the future. The collaborative efforts are focused on advancing small molecule development candidates which Merck will select for further pre-clinical and clinical development. Both partners will each receive low double digit million US dollar upfront payments and will be eligible for discovery, development, regulatory and commercial milestone payments and tiered royalties based on net sales.

Merck systematically explores data science and AI approaches to accelerate the discovery and delivery of breakthrough medicines. Integrating AI across R&D processes from identifying targets to clinical trials and product lifecycle management, is aimed at transforming drug discovery and development, bringing new medicines to patients faster and with higher probability of success. As the field evolves Merck will continue to deepen its existing AI and advanced analytics expertise while expanding partnerships and collaborations, ensuring the company remains at the forefront of innovation.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

责任编辑: admin

看新闻,关注新闻

猫扑网友:往日 °Cold
评论:令我感到骄傲和自豪的是,至今为止,地球仍被我踩在脚下。

天涯网友:醉眼的迷蒙.heart2/2
评论:每当我找到了成功的钥匙,就有人把锁给换了。

天猫网友:血统 FackEdison◎
评论:每个人出生时都是原创的,但可悲的是,很多人渐渐活成了盗版的。

搜狐网友:哥只是寂寞
评论:最美好的是爱情,最理解的是友情,最真诚的是亲情。

其它网友:memory’流年
评论:喜欢发呆的人,心里一定有另一个纯净的世界。

网易网友:离心   ■
评论:既来之则安之,有福不享是傻子。

淘宝网友:heart┃ 葬心
评论:我说过我爱你。没说我只爱你。

腾讯网友:春暖々花開
评论:长大成人这件事最恐怖的地方之一,在于,你或许会变成自己曾经最看不起的那种人。

百度网友:強顏歡笑ソ
评论:我愿意为你摘一颗星,只要你借给我足够高的椅子。

本网网友:私欲° 7/m
评论:一个女人的品位,在于她身边站着一个怎样品位的男人。

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!